Intraperitoneal Catumaxomab Therapy in a Cirrhotic Patient with Malignant Ascites due to Urethelial Carcinoma: A Case ReportKrawczyk M. · Zimmermann S. · Vidacek D. · Lammert F.
Department of Medicine II, Saarland University Medical Center, Homburg, Germany
Background: Refractory malignant ascites is a common complication in tumor patients. To date, chemotherapy and paracentesis represent the most widely used methods to relieve the symptoms. Lately, intraperitoneal therapy with catumaxomab, a trifunctional hybrid antibody, has been introduced for the treatment of malignant ascites, and its utility has been demonstrated in patients with distinct abdominal malignancies. Case Report: We report the first case of successful catumaxomab treatment of malignant ascites in a patient with advanced carcinoma of the urinary bladder and liver cirrhosis. Although at admission a largevolume paracentesis was needed every other day, paracentesis was no longer necessary after catumaxomab therapy. Conclusion: Catumaxomab might represent a safe treatment option for malignant ascites in the course of metastatic urothelial carcinoma, also in the setting of liver cirrhosis.
© 2012 S. Karger AG, Basel
Dr. med. Marcin Krawczyk
Department of Medicine II, Saarland University Medical Center
Kirrberger Str. 100, 66421 Homburg, Germany
Tel.: +49 6841 16-23242, Fax -23570
Published online: September 18, 2012
Number of Print Pages : 3
Onkologie (International Journal for Cancer Research and Treatment)
Vol. 35, No. 10, Year 2012 (Cover Date: Oktober 2012)
Journal Editor: Schmoll H.-J. (Halle/Saale), Hallek M. (Köln)
ISSN: 0378-584X (Print), eISSN: 1423-0240 (Online)
For additional information: http://www.karger.com/ONK